Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma

Camilo Jimenez,Yang Lu
DOI: https://doi.org/10.1097/rlu.0000000000004519
IF: 10.6
2023-04-07
Clinical Nuclear Medicine
Abstract:An 84-year-old man with history of metastatic pheochromocytoma/paraganglioma (mPPGL) received surgery 13 years ago, with recent biopsy-proven mPPGL in the T11. 123 I- MIBG scan showed MIBG -avid liver and osseous. Given his medical condition and body habitus (weight, 45 kg; height, 140 cm), the patient was treated with high-specific-activity 131 I- MIBG (Azedra) 300 mCi ×2. He tolerated the medication and was totally asymptomatic. Series 123 I- MIBG scan showed good responses till 22 months after the first treatment at the last visit. This is probably the oldest and smallest adult mPPGL patient treated with Azedra and with prolonged good response.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?